Literature DB >> 16236503

C8c-C15 monoseco-analogues of the phenanthroquinolizidine alkaloids julandine and cryptopleurine exhibiting potent anti-angiogenic properties.

Martin G Banwell1, Anna Bezos, Christopher Burns, Irma Kruszelnicki, Christopher R Parish, Stephen Su, Magne O Sydnes.   

Abstract

Four enantiomerically pure monoseco-analogues, 5, 7, 9, and 11, of the phenanthroquinolizidine alkaloid julandine (1) and four of congener cryptopleurine (2), viz. compounds 6, 8, 10, and 12, have been prepared and subjected to preliminary biological evaluation. These analogues show dramatically reduced cytotoxicity compared with the parent system 2 but they are, nevertheless, potent anti-angiogenic agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236503     DOI: 10.1016/j.bmcl.2005.09.032

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Antitumor agents 288: design, synthesis, SAR, and biological studies of novel heteroatom-incorporated antofine and cryptopleurine analogues as potent and selective antitumor agents.

Authors:  Xiaoming Yang; Qian Shi; Shuenn-Chen Yang; Chi-Yuan Chen; Sung-Liang Yu; Kenneth F Bastow; Susan L Morris-Natschke; Pei-Chi Wu; Chin-Yu Lai; Tian-Shung Wu; Shiow-Lin Pan; Che-Ming Teng; Jau-Chen Lin; Pan-Chyr Yang; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2011-06-28       Impact factor: 7.446

2.  Phenanthroindolizidines and Phenanthroquinolizidines: Promising Alkaloids for Anti-Cancer Therapy.

Authors:  Sherry R Chemler
Journal:  Curr Bioact Compd       Date:  2009-03-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.